- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00901147
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy
Study Overview
Status
Conditions
- Angioimmunoblastic T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma
- Peripheral T-cell Lymphoma (Not Otherwise Specified)
- Extranodal NK/T-cell Lymphoma Nasal Type
- Enteropathy- Type T-cell Lymphoma
- Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
- Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
Intervention / Treatment
Detailed Description
Peripheral T-cell lymphoma (PTCL) and NK/T-cell lymphoma are uncommon diseases that are prevalent in Asia. They are associated with poor prognosis when treated with conventional chemotherapeutic regimes. Their long term disease-free survivals are dismal with only 10-30% of patients surviving long term. More intensive regimens including high dose chemotherapy with autologous stem cell transplant have been tried as primary induction treatment, but have not been shown to be beneficial. Given the rarity of PTCL and NK/T-cell lymphoma, much of the literature consists of studies with small sample size and anecdotal case reports. Therefore, no consensus exists on the best therapeutic strategy for either newly diagnosed or relapsed disease. The failure of conventional chemotherapy in this regard suggests that novel therapies including epigenetic approaches and proteasome inhibition should be explored.
Preclinical data of bortezomib and histone deacetylase inhibitors (HDIs) in T-cell and NK/T-cell lymphoma cell lines are encouraging. Bortezomib and HDIs have also separately demonstrated activity in T and NK/T-cell lymphomas in phase II studies, leading to their separate developments in phase III studies. Demonstration of synergism in these 2 agents, in part due to their dependence on overlapping pathways, suggests that they should be explored as a combination, especially when treating a disease with a very unfavourable outcome. The purpose of this phase II study is to assess the efficacy of orally-administered panobinostat, a potent class I/II pan-deacetylase inhibitor with intravenous bortezomib in this patient population.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Centre
-
-
-
-
-
Kuala Lumpur, Malaysia, 56000
- Hospital Universiti Kebangsaan Malaysia ( HUKM )
-
-
Selangor
-
Subang Jaya, Selangor, Malaysia, 47500
- Subang Jaya Medical Centre
-
-
-
-
-
Singapore, Singapore, 169608
- Singapore General Hospital
-
Singapore, Singapore, 169608
- National Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed PTCL NOS, angioimmunoblastic T-cell lymphoma, extranodal NK/T-cell lymphoma nasal type, enteropathy- type T-cell lymphoma, hepatosplenic T-cell lymphoma, ALCL (ALK-1 negative), or patients with ALK 1 expressing ALCL (ALK-1 positive) who have relapsed disease after ASCT
- Age ≥21 years
- Written informed consent
- Progressive disease following at least one systemic therapy or refractory to at least one prior systemic therapy
- Measurable disease according to the IWC criteria and/or measurable bone marrow disease by flow cytometry or morphology
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Absolute neutrophil count of ≥1000 × 10(9)cells/L
- Serum potassium ≥3.8 mmol/L and magnesium ≥0.85 mmol/L (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria)
- Negative urine or serum pregnancy test on females of childbearing potential
- All females of childbearing potential and males must use an effective barrier method of contraception during the treatment period and for at least 1 month thereafter.
Exclusion Criteria:
- Chemotherapy or immunotherapy within 3 weeks of study entry
- Concomitant use of any other anti-cancer therapy
- Concomitant use of any other investigational agent
Any known cardiac abnormalities such as:
- Congenital long QT syndrome;
- QTcF interval >480 milliseconds (msec);
- A myocardial infarction within 12 months of study entry;
- Other significant ECG abnormalities including 2nd atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate < 50 beats/ min).
- An ECG recorded at screening showing significant ST depression (ST depression of ≥2 mm, measured from isoelectric line to the ST segment at a point 60 msec at the end of the QRS complex). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;
- Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction <40% by MUGA scan or <50% by echocardiogram and/or MRI;
- A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);
- Hypertrophic cardiomyopathy or restrictive cardiomyopathy from prior treatment or other causes (if in doubt, see ejection fraction criteria above);
- Any cardiac arrhythmia requiring anti-arrhythmic medication;
- Serum potassium <3.8 mmol/L or serum magnesium <0.85 mmol/L (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria)
- Concomitant use of drugs that may cause a prolongation of the QTcF
- Concomitant use of CYP3A4 inhibitors
- Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule
- Concomitant use of warfarin due to a potential drug interaction
- Clinically significant active infection
- Known infection with human immunodeficiency virus (HIV)
- Patient has known clinically active hepatitis B or C
- Previous extensive radiotherapy involving ≥30% of bone marrow (e.g., whole pelvis, half spine), excluding patients who have had total body irradiation as part of a conditioning regimen for stem cell transplant
- Major surgery within 2 weeks of study entry
- Peripheral neuropathy or neuropathic pain of Grade 2 or worse
- Platelet count <50 × 109 cells/L or platelet count <30 × 109 cells/L if bone marrow disease involvement is documented
- Serum creatinine >2.0 × ULN
- Patients who are pregnant or breast-feeding
- Patient has known hypersensitivity to any components of bortezomib (such as boron, mannitol), or panobinostat
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: panobinostat and bortezomib
Oral Panobinostat and intravenous bortezomib
|
oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective Response Rate
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to response, Duration of response, Progression-free survival, Overall survival, Safety and tolerability, Changes in disease-related symptoms and ECOG performance status.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Darryl Tan, MBBS MMED, Singapore General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphadenopathy
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Extranodal NK-T-Cell
- Immunoblastic Lymphadenopathy
- Enteropathy-Associated T-Cell Lymphoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Histone Deacetylase Inhibitors
- Bortezomib
- Panobinostat
Other Study ID Numbers
- SGH651
- SHF/CTG023/2008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angioimmunoblastic T-cell Lymphoma
-
Navy General Hospital, BeijingChinese PLA General HospitalRecruitingRelapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell LymphomaChina
-
The Lymphoma Academic Research OrganisationCelgeneActive, not recruitingRelapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell LymphomaFrance, Denmark, United Kingdom, Austria, Belgium
-
Huijing WuBeijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical GroupRecruitingAngioimmunoblastic T-cell LymphomaChina
-
Sun Yat-sen UniversityNot yet recruitingAngioimmunoblastic T-cell LymphomaChina
-
Ruijin HospitalActive, not recruitingAngioimmunoblastic T-cell LymphomaChina
-
Peking Union Medical College HospitalBeijing Longfu HospitalNot yet recruitingAngioimmunoblastic T-cell LymphomaChina
-
University of NebraskaNational Cancer Institute (NCI); Spectrum Pharmaceuticals, IncCompletedPeripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell LymphomaUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedAnaplastic Large Cell Lymphoma, ALK-Positive | Hepatosplenic T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Anaplastic Large Cell Lymphoma, ALK-Negative | Stage II Angioimmunoblastic T-cell Lymphoma | Stage II Enteropathy-Associated T-Cell Lymphoma | Stage III Angioimmunoblastic... and other conditionsUnited States
-
Qingdao UniversityUnknownAngioimmunoblastic T-cell LymphomaChina
-
Ou Bai, MD/PHDSecond Hospital of Jilin University; China-Japan Union Hospital, Jilin UniversityRecruitingAngioimmunoblastic T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedChina
Clinical Trials on panobinostat and bortezomib
-
University of ArkansasNovartisTerminated
-
Anand JillellaNovartis PharmaceuticalsCompletedMantle Cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedRelapse/Refractory Multiple MyelomaJapan
-
pharmaand GmbHCompletedMultiple MyelomaCanada, Spain, United States, Czechia, Turkey, France, Sweden, Korea, Republic of, Thailand, Belgium, Greece, Germany, Hungary, Russian Federation, Italy, Poland, Australia, Lebanon, Portugal, Norway, Brazil, Netherlands
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
Masonic Cancer Center, University of MinnesotaNovartis Pharmaceuticals; Millennium Pharmaceuticals, Inc.TerminatedPancreatic CancerUnited States
-
Centre Leon BerardCompleted
-
SCRI Development Innovations, LLCNovartis; Onyx Therapeutics, Inc.CompletedMultiple MyelomaUnited States
-
Novartis PharmaceuticalsTerminated
-
Dana-Farber Cancer InstituteNovartis; Brigham and Women's HospitalCompletedWaldenstrom's MacroglobulinemiaUnited States